Olema Pharmaceuticals (NASDAQ:OLMA) Insider Sells $2,804,000.00 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider Naseem Zojwalla sold 100,000 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $28.04, for a total value of $2,804,000.00. Following the transaction, the insider directly owned 53,997 shares in the company, valued at $1,514,075.88. This trade represents a 64.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Naseem Zojwalla also recently made the following trade(s):

• On Tuesday, December 23rd, Naseem Zojwalla sold 99,509 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $27.66, for a total transaction of $2,752,418.94.
• On Friday, December 19th, Naseem Zojwalla sold 70,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $28.20, for a total transaction of $1,974,000.00.

Olema Pharmaceuticals Stock Down 1.2%

Olema Pharmaceuticals stock opened at $27.34 on Friday. Olema Pharmaceuticals, Inc. has a 52 week low of $2.86 and a 52 week high of $36.26. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of -14.62 and a beta of 1.87. The company’s 50-day moving average price is $19.28 and its two-hundred day moving average price is $10.80. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). On average, analysts expect that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on OLMA. UBS Group restated a “buy” rating on shares of Olema Pharmaceuticals in a report on Monday, October 20th. Guggenheim began coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, October 8th. They set a “buy” rating and a $20.00 price objective for the company. Zacks Research upgraded shares of Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 9th. Citigroup raised their target price on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, Oppenheimer lifted their price target on shares of Olema Pharmaceuticals from $45.00 to $48.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Olema Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $40.50.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its stake in Olema Pharmaceuticals by 4.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 349,023 shares of the company’s stock worth $1,312,000 after purchasing an additional 16,073 shares during the period. Deutsche Bank AG lifted its holdings in shares of Olema Pharmaceuticals by 38.1% in the first quarter. Deutsche Bank AG now owns 54,329 shares of the company’s stock valued at $204,000 after purchasing an additional 14,998 shares in the last quarter. Invesco Ltd. boosted its position in shares of Olema Pharmaceuticals by 208.9% in the first quarter. Invesco Ltd. now owns 50,810 shares of the company’s stock worth $191,000 after buying an additional 34,362 shares during the period. Nuveen LLC acquired a new stake in shares of Olema Pharmaceuticals in the first quarter worth $1,295,000. Finally, Hsbc Holdings PLC grew its holdings in shares of Olema Pharmaceuticals by 56.9% during the first quarter. Hsbc Holdings PLC now owns 15,698 shares of the company’s stock valued at $58,000 after buying an additional 5,693 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.